EDIT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
11.9M
+320.0%
2.8M
-88.6%
24.7M
+228.0%
7.5M
+110.8%
3.6M
Cost of Revenue
0
0
0
0
0
Gross Profit
11.9M
+320.0%
2.8M
-88.6%
24.7M
+228.0%
7.5M
+110.8%
3.6M
Operating Expenses
30.4M
+9.4%
27.8M
-14.3%
32.5M
+1.3%
32.1M
-41.8%
55.1M
R&D
20.2M
+14.7%
17.6M
-35.8%
27.4M
+38.6%
19.8M
+22.2%
16.2M
SG&A
11.6M
+13.4%
10.2M
-9.9%
11.4M
-7.8%
12.3M
-4.2%
12.9M
Operating Income
-18554000
+25.8%
-25003000
-222.4%
-7755000
+68.4%
-24548000
+52.4%
-51544000
EBITDA
-19477000
+20.6%
-24520000
-85.6%
-13211000
+44.6%
-23827000
-0.8%
-23628000
Net Income
-18230000
+27.0%
-24982000
-344.5%
-5620000
+77.6%
-25117000
+52.8%
-53235000
EPS (Basic)
$-0.15
+42.3%
$-0.26
-333.3%
$-0.06
+78.6%
$-0.28
+55.6%
$-0.63
EPS (Diluted)
$-0.15
+42.3%
$-0.26
-333.3%
$-0.06
+78.6%
$-0.28
+55.6%
$-0.63
Shares (Diluted)
119.3M
+21.9%
97.9M
+0.5%
97.4M
+8.1%
90.1M
+6.7%
84.4M
Editas Medicine (EDIT) โ€” Financials